136 related articles for article (PubMed ID: 36205930)
1. Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing.
Freeman T; Taneja C; Ohori NP; Wald AI; Skaugen J; Yip L; Kim S; Ferris RL; Nikiforova MN; Roy S; Nikiforov YE
Endocr Relat Cancer; 2022 Dec; 29(12):657-664. PubMed ID: 36205930
[TBL] [Abstract][Full Text] [Related]
2. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
3. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
4. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
[TBL] [Abstract][Full Text] [Related]
5. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
6. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
7. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
8. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
9. Thyroid Ultrasound-Guided Fine-Needle Aspiration Cytology Results: Observed Increase in Indeterminate Rate over the Past Decade.
Manning AM; Yang H; Falciglia M; Mark JR; Steward DL
Otolaryngol Head Neck Surg; 2017 Apr; 156(4):611-615. PubMed ID: 28118554
[TBL] [Abstract][Full Text] [Related]
10. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?
Figge JJ; Gooding WE; Steward DL; Yip L; Sippel RS; Yang SP; Scheri RP; Sipos JA; Mandel SJ; Mayson SE; Burman KD; Folek JM; Haugen BR; Sosa JA; Parameswaran R; Tan WB; Nikiforov YE; Carty SE
Thyroid; 2021 Nov; 31(11):1673-1682. PubMed ID: 34340592
[No Abstract] [Full Text] [Related]
11. Diagnostic utility of fine needle aspiration cytology in pediatric thyroid nodules based on Bethesda Classification.
Jiang W; Phillips SA; Newbury RO; Naheedy JH; Newfield RS
J Pediatr Endocrinol Metab; 2021 Apr; 34(4):449-455. PubMed ID: 33629571
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
Hall EA; Hartzband P; VanderLaan PA; Nishino M
Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
[TBL] [Abstract][Full Text] [Related]
13. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
[TBL] [Abstract][Full Text] [Related]
14. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
[TBL] [Abstract][Full Text] [Related]
15. Role of Ancillary Techniques in Thyroid Cytology Specimens.
Nishino M; Krane JF
Acta Cytol; 2020; 64(1-2):40-51. PubMed ID: 30947167
[TBL] [Abstract][Full Text] [Related]
16. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
[TBL] [Abstract][Full Text] [Related]
17. Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fine-needle aspirates diagnosed as follicular neoplasm of Hürthle cell (oncocytic) type.
Landau MS; Nikiforov YE; Ohori NP; Chiosea SI
Cancer Cytopathol; 2021 Oct; 129(10):788-797. PubMed ID: 33901345
[TBL] [Abstract][Full Text] [Related]
18. An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules.
Taccogna S; Papini E; Novizio R; D'Angelo M; Turrini L; Persichetti A; Pontecorvi A; Guglielmi R
Front Endocrinol (Lausanne); 2022; 13():1078019. PubMed ID: 36531453
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
[TBL] [Abstract][Full Text] [Related]
20. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
[Next] [New Search]